Prospective double-blind crossover study of Camellia sinensis (Green tea) in dyslipidemias;Estudo prospectivo, duplo cego e cruzado da Camellia sinensis (Chá verde) nas dislipidemias

Arquivos Brasileiros de Cardiologia

Volumn 93, Issue 2, 2009, Pages 128-134

  Batista, Gesiani De Almeida Pierin ^a   Pereira Da Cunha, Cláudio L ^a   Scartezini, Mariléia ^a   Von Der Heyde, Raul ^a   Bitencourt, Murílo G ^a   De Melo, Sandra Fabrício ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Camellia sinensis; Case control studies; Dyslipidemias; Epidemiologic studies; Phytotherapy; Thea sinensis

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; GREEN TEA EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CALORIC INTAKE; CARBOHYDRATE INTAKE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; FAT INTAKE; HUMAN; LOW FAT DIET; PROSPECTIVE STUDY; PROTEIN INTAKE; TEA; TREATMENT DURATION;

ADULT; AGED; CAMELLIA SINENSIS; DIET, FAT-RESTRICTED; DYSLIPIDEMIAS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PLANT EXTRACTS; TEA; YOUNG ADULT;

EID: 70350711919     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2009000800010     Document Type: Article

References (36)

1. Korolkovas A. A riqueza potencial de nossa flora. Rev Bras Farmacognosia. 1996; 1: 1-7.
2. Rates SMK. Plants as source of drugs. Toxicon. 2001; 39: 603-613
3. Maron DJ, Sibilo GL, Sheng CN, Swu ZG, Li YH, Chen H, et al. Cholesterol-lowering effect of a theaflavin-enriched green tea extract: a randomized controlled trial. Arch Intern Med. 2003; 163: 1448-1453 (Pubitemid 36758917)
4. Tokunaga S, White IR, Frost C, Tanaka K, Kono S. Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan. Ann Epidemiol. 2002; 12: 157-165 (Pubitemid 34189717)
5. Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med. 1995; 155 (4): 381-386
6. Mukamal KJ, Maclure M, Muller JE. Tea consumption and mortality after acute myocardial infarction. Circulation. 2002; 105: 2476-2481 (Pubitemid 34568967)
7. Hodgson JM, Puddey IB, Croft KD. Acute effects of ingestion of black and green tea on lipoprotein oxidation. Am J Clin Nutr. 2000; 71 (5): 1103-1107
8. Leung LK, Su RCY, Zesheng Z, Huang Y, Chen ZY. Theaflavins in black and catechins in green tea are equally effective antioxidants. J Nutr. 2001; 131: 2248-2251 (Pubitemid 32851864)
9. Hodgson JM, Croft KD, Mori TA, Burke V, Beilin LJ, Puddley IB. Regular ingestion of tea does not inhibit in vivo lipid peroxidation in humans. J Nutr. 2002; 132: 55-58 (Pubitemid 34042455)
10. Duffy SJ, Vita JA, Holbrook M, Swerdloff PL, Keaney JF Jr. Effect of acute and chronic tea consumption on platelet aggregation in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001; 21 (6): 1084-1089 (Pubitemid 34168673)
11. Simin L, Manson JAE, Lee IM, Cole SR, Hennekens CH, Willett WC, et al. Fruit and vegetable intake and risk of cardiovascular disease: the Women's Health Study. Am J Clin Nutr. 2000; 72: 922-928
12. Siddiqui IA, Afaq F, Adhami VM, Ahmad N, Mukhtar H. Antioxidants of the beverage tea in promotion of human health. Antioxid Redox Signal. 2004; 6 (3): 571-582 (Pubitemid 38656104)
13. Chopra D. The Chopra Center Herbal Handbook. USA: Three Rivers Press; 2000.
14. Ody P. The Herb Society's complete medicinal herbal. London: Dorling Kindersley; 1993.
15. Sociedade Brasileira de Cardiologia. Sociedade Brasileira de Hipertensão. V Diretrizes Brasileiras de Hipertensão arterial. 2006. (on line). [acesso em 2007 setembro 10]. Disponível em: http://publicacoes.cardiol.br/consenso/2006/VDiretriz-HA.pdf
16. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) National Cholesterol Education Program (NCEP). Expert panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults. Circulation. 2002; 106 (25): 3143-3421
17. Santos RD, Spósito AC, Santos JE, Fonseca FH, Moriguchi EH, Martinez TLR, et al. Programa de avaliação nacional do conhecimento sobre prevenção da aterosclerose (PANDORA): como tem sido feito o tratamento das dislipidemias pelos médicos brasileiros. Arq Bras Cardiol. 2000; 75: 289-295
18. Santos Filho RD, Martinez TLR. Fatores de risco para doença cardiovascular: velhos e novos fatores de risco, velhos problemas! Arq Bras Endocrinol Metab. 2002; 46 (3): 212-214
19. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol. 1998; 4 (Suppl A): 5A-10A.
20. Server PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149-1158 (Pubitemid 36398384)
21. Kannel WB, Castelli WP, Gordon T. Serum cholesterol lipoproteins and of coronary heart disease: the Framinghan study. Ann Int Med. 1971; 74: 1-12.
22. nd. ed. Stuttgart: FK Schattauer; 1993.
23. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. For the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998; 279: 1615-1622
24. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvatatin Survival Study (4S). Lancet. 1994; 344: 1383-1389
25. Shepherd J, Blauw GJ, Murphy MB. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet. 2002; 360: 1623-1630
26. MRC/BHF heart protection study of cholesterol lowering with sinvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22. (Pubitemid 34756487)
27. rd. ed. New York: Gower Medical Publishing; 1990.
28. Kannel WB, Wilson PW, Nam BH, D'Agostino RB. Risk stratification of obesity as a coronary risk factor. Am J Cardiol. 2002; 90: 697-701. (Pubitemid 35279387)
29. Scott M, Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002; 105 (23): 2696-2698 (Pubitemid 34615135)
30. a ed. São Paulo: Roca; 2002.
31. Davies MJ, Judd JT, Baer DJ, Clevidence BA, Paul DR, Edwards AJ, et al. Black tea consumption reduces total and LDL cholesterol in mildly hypercholesterolemic adults. J Nutr. 2003; 133: 3298S-3302S.
32. Kajimoto O, Kajimoto Y, Yabune M, Nozawa A, Nagata K, Kakuda T. Tea catechins reduce serum cholesterol levels in mild borderline hypercholesterolemic patients. J Clin Biochem Nutr. 2003; 33: 101-111 (Pubitemid 38470728)
33. Kajimoto O, Kajimoto Y, Yabune M, Nakamura T, Kotani K, Suzuki Y, et al. Tea catechins with a galloyl moiety reduce body weight and fat. J Health Sci. 2005; 51: 161-171 (Pubitemid 40628461)
34. Geleijnse JM, Launer LJ, Van der Kuip DA, Hofman A, Witteman JC. Inverse association of tea and flavonoid intakes with incident myocardial infarction: the Rotterdam Study. Am J Clin Nutr. 2002; 75 (5): 880-886 (Pubitemid 34441257)
35. Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr. 1999; 70: 1040-1045
36. Chantre P, Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine. 2002; 9(1): 9 (3-8. (Pubitemid 34184203)